Press release
Alzheimer's Disease Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron, TrueBinding, Alector
The Alzheimer's Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Alzheimer's Disease Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alzheimer's Disease Market.
Some of the key takeaways from the Alzheimer's Disease Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Alzheimer's Disease treatment therapies with a considerable amount of success over the years.
*
Alzheimer's Disease companies working in the treatment market are Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron, TrueBinding, Alector, Cognition Therapeutics, Anavex Life Sciences, Eisai Co Ltd, Cassava Sciences, Inc., Karuna Therapeutics, BioVie, and others, are developing therapies for the Alzheimer's Disease treatment
*
Emerging Alzheimer's Disease therapies in the different phases of clinical trials are- NRDN-201, ST-501, SNK 01, ASN51, TB 006, AL002, CT-1812, Blarcamesine, E 2814, Simufilam, KarXT, NE3107, and others are expected to have a significant impact on the Alzheimer's Disease market in the coming years.
*
In June 2025, The UAB Brain Aging and Memory Clinic, which opened in spring 2024, ushers in a new chapter of care for Alzheimer's disease and memory disorders in Alabama and the surrounding region. This facility has played a key role in supporting clinical trials, strengthening UAB's position as a leading site for testing the latest generation of anti-Alzheimer therapies.
*
In July 2025, INmune Bio's stock dropped over 50% after its TNF inhibitor failed to show efficacy in Alzheimer's patients in a Phase II trial. The MINDFuL study (NCT05318976) tested XPro (pegipanermin), a selective soluble TNF inhibitor, in early Alzheimer's patients with inflammatory biomarkers. While no overall benefit was observed at the six-month mark in the intent-to-treat group, patients with two or more inflammation biomarkers showed a modest 0.27-point improvement on the Early Mild Alzheimer's Cognitive Composite (EMACC) and a -0.20 change in pTau217 blood levels. INmune Bio suggests this subgroup might benefit from XPro.
*
In April 2025, Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has awarded Fast Track designation to BIIB080, an experimental antisense oligonucleotide (ASO) therapy targeting tau, for treating Alzheimer's disease. This designation aims to accelerate the development and review process of investigational drugs addressing serious diseases with unmet medical needs.
*
In March 2025, Acumen Pharmaceuticals completed enrollment for its multi-center, double-blind Phase II ALTITUDE-AD trial evaluating the humanized monoclonal antibody sabirnetug (ACU193) in patients with early Alzheimer's disease. Sabirnetug is noted as the first antibody to selectively target amyloid beta oligomers (AOs), a toxic form of amyloid beta implicated in the early stages of Alzheimer's. The ALTITUDE-AD trial, initiated last year, is a randomized, placebo-controlled study that has enrolled 542 participants across Canada, the EU, the US, and the UK.
*
In February 2025, AUS University has initiated a prevention trial to study Eli Lilly's investigational drug remternetug in young adults, aiming to halt the progression of Alzheimer's disease. Meanwhile, Washington University School of Medicine has announced the enrollment of the first participants in its Alzheimer's disease DIAN-TU-002 primary prevention trial (NCT06647498). This study plans to recruit 240 individuals from families carrying mutations in one of three key genes linked to Alzheimer's, who have a family history placing them at risk of developing the disease in their 30s, with some participants as young as 18 years old.
Alzheimer's Disease Overview
Alzheimer's Disease is a progressive neurodegenerative disorder that primarily affects memory, thinking, and behavior. It is the most common cause of dementia in older adults. Alzheimer's occurs when abnormal protein deposits (like beta-amyloid plaques and tau tangles) build up in the brain, leading to the loss of nerve cells and brain shrinkage.
Early symptoms include forgetfulness, confusion, and difficulty with everyday tasks. As the disease advances, it leads to severe memory loss, personality changes, and dependence on others for care. Currently, there is no cure, but treatments aim to slow progression and improve quality of life.
Get a Free Sample PDF Report to know more about Alzheimer's Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight [https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Alzheimer's Disease Drugs Under Different Phases of Clinical Development Include:
*
NRDN-201: Neurodon
*
ST-501: Sangamo Therapeutics
*
SNK 01: NKGen Biotech
*
ASN51: Asceneuron
*
TB 006: TrueBinding
*
AL002: Alector
*
CT-1812: Cognition Therapeutics
*
Blarcamesine: Anavex Life Sciences
*
E 2814: Eisai Co Ltd
*
Simufilam: Cassava Sciences, Inc.
*
KarXT: Karuna Therapeutics
*
NE3107: BioVie
Alzheimer's Disease Route of Administration
Alzheimer's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Alzheimer's Disease Molecule Type
Alzheimer's Disease Products have been categorized under various Molecule types, such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Alzheimer's Disease Pipeline Therapeutics Assessment
*
Alzheimer's Disease Assessment by Product Type
*
Alzheimer's Disease By Stage and Product Type
*
Alzheimer's Disease Assessment by Route of Administration
*
Alzheimer's Disease By Stage and Route of Administration
*
Alzheimer's Disease Assessment by Molecule Type
*
Alzheimer's Disease by Stage and Molecule Type
DelveInsight's Alzheimer's Disease Report covers around 220+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Alzheimer's Disease product details are provided in the report. Download the Alzheimer's Disease pipeline report to learn more about the emerging Alzheimer's Disease therapies [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Alzheimer's Disease Therapeutics Market include:
Key companies developing therapies for Alzheimer's Disease are - AbbVie, Inc., Teva Pharmaceuticals Ltd., Eisai Co., Ltd., Janssen Pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Zydus Lifesciences Ltd (CADILA), Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd, Aurobindo Pharma Ltd, Amneal Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Viatris Inc., Lupin Ltd, Cipla Ltd., Torrent Pharmaceuticals Ltd., Unichem laboratories ltd, Lannett Inc., and others.
Alzheimer's Disease Pipeline Analysis:
The Alzheimer's Disease pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Alzheimer's Disease with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer's Disease Treatment.
*
Alzheimer's Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Alzheimer's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alzheimer's Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Alzheimer's Disease drugs and therapies [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Alzheimer's Disease Pipeline Market Drivers
*
Increase in prevalence of Alzheimer's Disease (AD), rising geriatric population are some of the important factors that are fueling the Alzheimer's Disease Market.
Alzheimer's Disease Pipeline Market Barriers
*
However, clinical trials are more complicated, costly, and slower than trials for other diseases., lack of clear diagnosis and other factors are creating obstacles in the Alzheimer's Disease Market growth.
Scope of Alzheimer's Disease Pipeline Drug Insight
*
Coverage: Global
*
Key Alzheimer's Disease Companies: Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron, TrueBinding, Alector, Cognition Therapeutics, Anavex Life Sciences, Eisai Co Ltd, Cassava Sciences, Inc., Karuna Therapeutics, BioVie, and others
*
Key Alzheimer's Disease Therapies: NRDN-201, ST-501, SNK 01, ASN51, TB 006, AL002, CT-1812, Blarcamesine, E 2814, Simufilam, KarXT, NE3107, and others
*
Alzheimer's Disease Therapeutic Assessment: Alzheimer's Disease current marketed and Alzheimer's Disease emerging therapies
*
Alzheimer's Disease Market Dynamics: Alzheimer's Disease market drivers and Alzheimer's Disease market barriers
Request for Sample PDF Report for Alzheimer's Disease Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Alzheimer's Disease Report Introduction
2. Alzheimer's Disease Executive Summary
3. Alzheimer's Disease Overview
4. Alzheimer's Disease- Analytical Perspective In-depth Commercial Assessment
5. Alzheimer's Disease Pipeline Therapeutics
6. Alzheimer's Disease Late Stage Products (Phase II/III)
7. Alzheimer's Disease Mid Stage Products (Phase II)
8. Alzheimer's Disease Early Stage Products (Phase I)
9. Alzheimer's Disease Preclinical Stage Products
10. Alzheimer's Disease Therapeutics Assessment
11. Alzheimer's Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Alzheimer's Disease Key Companies
14. Alzheimer's Disease Key Products
15. Alzheimer's Disease Unmet Needs
16 . Alzheimer's Disease Market Drivers and Barriers
17. Alzheimer's Disease Future Perspectives and Conclusion
18. Alzheimer's Disease Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=alzheimers-disease-pipeline-2025-detailed-clinical-trials-and-fdaapproved-therapies-review-by-delveinsight-neurodon-sangamo-therapeutics-nkgen-biotech-asceneuron-truebinding-alector]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Disease Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron, TrueBinding, Alector here
News-ID: 4150496 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
